|
|
Article: Startup Alvine Aims At Celiac Disease, Closes $21M Round.
- Article from:
- BIOWORLD Today
- Article date:
- November 3, 2009
CopyrightCOPYRIGHT 2009 A Thomson Healthcare Company. This material is published under license from the publisher through the Gale Group, Farmington Hills, Michigan. All inquiries regarding rights should be directed to the Gale Group. (Hide copyright information)
|
Staff Writer
Founded about a year ago to develop treatments for celiac disease, Alvine Pharmaceuticals Inc. recently raised $21 million in its Series A round to advance its lead product through proof-of-concept studies.
Celiac disease, also known as celiac sprue, is an inherited autoimmune disorder triggered by the consumption of foods containing gluten, a cereal grain protein. Believed to be fairly common - affecting as many as one in 100 people in the U.S. - celiac disease historically has been under-diagnosed with no available drug therapy, said Alvine co-founder Chaitan Khosla, a professor at Stanford University who has "a long-standing interest" in ...